Results 151 to 160 of about 950,583 (268)

Dynamic Changes in Metabolic Syndrome and Risk of Hepatocellular Carcinoma: Evidence From a Nationwide Japanese Cohort

open access: yesLiver International Communications, Volume 7, Issue 4, December 2026.
ABSTRACT Aim Metabolic syndrome (MetS) is a known risk factor for hepatocellular carcinoma (HCC), but the impact of cumulative MetS burden and changes in MetS status over time remains unclear. This study aimed to assess these associations using a large‐scale Japanese health dataset.
Yutaka Yata   +9 more
wiley   +1 more source

A Confirmatory, Dual Center Nonhuman Primate Study on the Efficacy of Novel Oropharyngeal Spray Immunization With an Adenoviral Vector Vaccine Against RSV—Important Lessons Learned

open access: yesJournal of Medical Primatology, Volume 55, Issue 6, December 2026.
ABSTRACT Background In a randomized, blinded, dual center study across two European primate research facilities, we evaluated the immunogenicity and protective efficacy of a DNA prime—oropharyngeal adenoviral boost vaccination strategy against respiratory syncytial virus (RSV).
Matthias Tenbusch   +15 more
wiley   +1 more source

Anti‐Viral Treatment Eligibility and Treatment Uptake Among People With Chronic Hepatitis B in Australia: The REACH‐B Study

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Treatment indication for chronic hepatitis B (CHB) varies across clinical guidelines. This study evaluated treatment eligibility and uptake in a large Australian cohort of people with CHB. The REACH‐B study recruited people with CHB managed through a national network of healthcare services.
Behzad Hajarizadeh   +28 more
wiley   +1 more source

Increasing HCV Diagnosis and Treatment Uptake Among Community‐Recruited People Who Inject Drugs in Athens, Greece, During the Transition to Unrestricted Access to Direct‐Acting Antivirals

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Eliminating hepatitis C requires focusing efforts on people who inject drugs (PWID). The ARISTOTLE HCV‐HIV program aimed to increase HCV and HIV diagnosis and linkage to care among PWID, particularly those currently injecting and not linked to opioid agonist treatment (OAT).
Sotirios Roussos   +24 more
wiley   +1 more source

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

open access: yes
Transfusion, EarlyView.
Nabiha H. Saifee   +24 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Sofosbuvir‐Based Therapy in Chinese Children and Adolescents With Chronic HCV Infection: A Retrospective Multicentre Study

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 12, December 2026.
ABSTRACT Few direct‐acting antiviral regimens are approved in China for children and adolescents with chronic hepatitis C virus (HCV) infection and data are limited on their efficacy and safety in this population. This retrospective, multi‐centre study aimed to assess the real‐world effectiveness and safety of ledipasvir/sofosbuvir (LDV/SOF) and ...
Li Liu   +12 more
wiley   +1 more source

[Anti-HCV and HCV RNA in patients with the primary Sjögren syndrome].

open access: yesPrzeglad epidemiologiczny, 2009
The subject of study were 104 patients with the primary Sjögren Syndrome (p. Sj. s.) in whom markers of hepatitis C infection were investigated. All the patients fulfilled the criteria of the European Expert Group of the Sjögren Syndrome. Antibodies anti-HCV were found in 20 patients (19.2%) and HCV-RNA found in 5 patients (4.8%).
Kazimierz, Madaliński   +6 more
openaire   +1 more source

Comparison of hepatitis C virus (HCV) RNA and anti-HCV results and evaluation of the relationship between transaminase levels

open access: yes, 2007
In this retrospective study, the data of hepatitis C virus (HCV) markers (anti-HCV and HCV-RNA) obtained from the patients who were prediagnosed and/or diagnosed as HCV infection have been comparatively evaluated and the relationship between these ...
Akguen, Yurdanur   +2 more
core  

Reductions in Advanced Chronic Liver Disease Among People Who Inject Drugs: The ETHOS Engage Study

open access: yesLiver International, Volume 46, Issue 12, December 2026.
ABSTRACT Background and Aims Liver disease is a significant risk for people who inject drugs due to the high burden of hepatitis C virus (HCV). There is limited data on the impact of the direct‐acting antiviral (DAA) therapy era on liver disease among people who inject drugs.
Anna Conway   +161 more
wiley   +1 more source

Absence of HCV RNA in Cervicovaginal Fluids of HCV Viremic Pregnant Women [PDF]

open access: yesFertility and Sterility, 2000
T. Persico   +5 more
openaire   +1 more source

Home - About - Disclaimer - Privacy